The consensus estimate for Q3 2025 revenue is $0.51 billion, and the earnings are expected to come in at -$0.20 per share.
Generation LNP Advancements enhance potency and safety, expand delivery beyond the liver, and enable broader therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback